Dr. David Weaver, PhD
David Weaver is currently a Research, Development, and Strategy Consultant in the biotech and pharmaceutical industry, utilizing his broad experience in Clinical Development, Translational Medicine, and preclinical discovery and validation. David also serves on the Scientific Advisory Boards and as a Scientific Advisor in several Biotech companies.
David was Vice President of Translational Medicine at Verastem Oncology, holding various Research and Clinical Development leadership roles from 2011-2020. Dr. Weaver was instrumental to the submission and FDA approval of COPIKTRATM (duvelisb, PI3K inhibitor) in 2018 for oncology indications, and guided the licensing and development of numerous oral agents targeting immune-oncology and other cancer mechanisms through many clinical trials (defactinib (Pfizer), CH5126766 (Chugai), VS-4718 (Poniard), VS-5584). Prior to Verastem, Dr. Weaver was a founder and CSO at On-q-ity for 5 years, developing medical devices for personalized medicine and cancer diagnostics (OnQChipTM). He was previously Head of Biology at a Daiichi-Sankyo US-based subsidiary focused on immune disease and cardiovascular drug development.
Prior to his pharmaceutical roles, Dr. Weaver was an Associate Professor at Harvard, a faculty member of the Immune Disease Institute and the Dana-Farber Cancer Institute. Throughout his career, Dr. Weaver has been instrumental in patenting and publishing innovations for biomedical development and scientific discoveries.